secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
CIK:        0001757499
Form:       8-K
Filed at:   2025-10-21T23:59:59+00:00
Accession:  0001493152-25-018788
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 1.01, 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shuttle Pharma signs $10M term sheet to buy Molecule assets; CRO Theradex terminates, seeks $1.09M
--------------------------------------------------------------------------------

- Binding term sheet for $10M purchase of substantially all assets and liabilities of Molecule; consideration in cash and stock per Shuttle's sole discretion, with milestones.
- CRO Theradex terminated Master Agreement on Oct 15, 2025, demanding immediate payment of $1.091M; if unpaid in 30 days, services will cease.
- Theradex is Shuttle's primary CRO; termination threatens clinical trial operations and requires immediate cash payment.
- Transaction subject to due diligence, board approval, definitive agreements; exclusivity period of 90 days from Oct 20, 2025.
- Shuttle intends to retain Molecule's CEO ZT Zhang for post-transaction transition and integration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1757499/000149315225018788/0001493152-25-018788-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1757499/000149315225018788/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-018788

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer